{"id":476708,"date":"2021-04-15T07:33:18","date_gmt":"2021-04-15T11:33:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/trevena-inc-announces-presentations-of-olinvyk-health-economic-models-at-amcp-2021-annual-meeting\/"},"modified":"2021-04-15T07:33:18","modified_gmt":"2021-04-15T11:33:18","slug":"trevena-inc-announces-presentations-of-olinvyk-health-economic-models-at-amcp-2021-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/trevena-inc-announces-presentations-of-olinvyk-health-economic-models-at-amcp-2021-annual-meeting\/","title":{"rendered":"Trevena, Inc. Announces Presentations of OLINVYK\u2122 Health Economic Models at AMCP 2021 Annual Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">&#8212;<\/p>\n<p align=\"justify\">\n        <em>Models demonstrate substantial overall cost savings for hospitals when using OLINVYK compared to IV morphine in postoperative care<\/em>\n      <\/p>\n<p align=\"justify\">\n        <em>&#8212;<\/em>\n      <\/p>\n<p align=\"justify\">CHESTERBROOK, Pa., April  15, 2021  (GLOBE NEWSWIRE) &#8212; <strong>Trevena, Inc. (Nasdaq: TRVN)<\/strong>, a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced two poster presentations at the AMCP 2021 Annual Meeting. The conference was held virtually from April 13<sup>th<\/sup> to 14<sup>th<\/sup>, 2021.<\/p>\n<p align=\"justify\">The posters highlight two health economic models developed for OLINVYK (oliceridine) injection, which estimate the budget impact of OLINVYK compared to IV morphine when used on-demand in a hospital setting for postoperative pain. A \u201cBase Case\u201d model assumes a broad patient population. A \u201cHigh Risk\u201d model limits the population to patients who are both elderly (\u2265 65 years old) and obese (BMI \u2265 30 kg\/m<sup>2<\/sup>), part of the Company\u2019s initial core focus for launch. Both models were developed using AE incidence rates from the OLINVYK Phase 3 program and AE cost estimates from the published literature and claims data as referenced in the posters.<\/p>\n<p align=\"justify\">\u201cPublishing these health economic models is the latest accomplishment in our ongoing launch of OLINVYK,\u201d said Mark Demitrack, M.D., Senior Vice President and Chief Medical Officer of Trevena, Inc. \u201cThese models form a critical component of the comprehensive product dossier for OLINVYK, and I am pleased to have this opportunity to share these compelling cost offset findings with key hospital stakeholders.\u201d<\/p>\n<p align=\"justify\">One of the posters, \u201cBudget Impact Analysis for Oliceridine in the Management of Moderate-to Severe Acute Postoperative Pain,\u201d was selected by the conference for a Gold Ribbon. This designation was awarded based on the same criteria used by <em>Journal of Managed Care &amp; Specialty Pharmacy <\/em>to evaluate manuscripts and was only given to 20% of all submitted abstracts.<\/p>\n<p align=\"justify\">\n        <strong>Poster Details<\/strong>\n      <\/p>\n<ol style=\"list-style-type:decimal\">\n<li style=\"margin-bottom:12pt;text-align:justify\">\n          <strong>Base Case Model:<\/strong> \u201cBudget Impact Analysis for Oliceridine in the Management of Moderate-to Severe Acute Postoperative Pain\u201d (Poster #U12)<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:12pt;text-align:justify\">OLINVYK is associated with a ~$230,000 decrease in total cost of care per 1,000 patients compared to IV morphine.<\/li>\n<li style=\"margin-bottom:12pt;text-align:justify\">These cost savings are due to reduced AEs for OLINVYK-treated patients, as observed in the Phase 3 pivotal trials, and using a conservative, low-end estimate of AE costs based on government and published literature sources.<\/li>\n<\/ul>\n<\/li>\n<li style=\"margin-bottom:12pt;text-align:justify\">\n          <strong>High Risk Model:<\/strong> \u201cCost Effectiveness Analysis of Oliceridine Compared with Morphine in The Management of Postoperative Moderate to Severe Acute Pain in a High Risk Population\u201d (Poster #U18)<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:12pt;text-align:justify\">OLINVYK is associated with savings of ~$364,000 in total cost of care per 1,000 patients, due to reduced AEs compared to IV morphine. The model estimates that the total cost of care associated with IV morphine would exceed $1.25M per 1,000 patients.<\/li>\n<\/ul>\n<\/li>\n<\/ol>\n<p align=\"justify\">All posters can be found at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PRfViVZdFhgR58ox9cOsmbAPIlzvVXeq1rgjFd7LHeegMuH8Hpcwha5UWSYz65lE-h0sXkVnUBDBUohbx2qR6qsA797O6Q8ttlNeVPCNvK3BwUj7Sg7VEC6_AhoYjwzy\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.trevena.com\/publications<\/a>. While the cost savings in these health economic models cannot be guaranteed, they are based on generally accepted methodology, and pharmacy and therapeutics committees typically review health economic models when making drug formulary decisions.<\/p>\n<p align=\"justify\">\n        <strong>About OLINVYK\u2122 (oliceridine) injection<\/strong>\n      <\/p>\n<p align=\"justify\">OLINVYK is a new chemical entity approved by the FDA in August 2020. OLINVYK contains oliceridine, a Schedule II controlled substance with a high potential for abuse similar to other opioids. It is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. OLINVYK is available in 1 mg\/1 mL and 2 mg\/2 mL single-dose vials, and a 30 mg\/30 mL single-patient-use vial for patient-controlled analgesia (PCA). Approved PCA doses are 0.35 mg and 0.5 mg and doses greater than 3 mg should not be administered. The cumulative daily dose should not exceed 27 mg. Please see Important Safety Information, including the BOXED WARNING, and full prescribing information at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MjsChohkm3RxRrf4_nCu4LYGDJfKYz2TI0jVgLDPvPvAJCBhIrk--z7ayzSX1HM_AQNWx-dWLPjShiupzLEJjw==\" rel=\"nofollow noopener\" target=\"_blank\">www.OLINVYK.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Trevena<\/strong>\n      <\/p>\n<p align=\"justify\">Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK\u2122 (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company\u2019s novel pipeline is based on Nobel Prize winning research and includes four differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, TRV045 for epilepsy and chronic neuropathic pain, and TRV027 for acute respiratory distress syndrome and abnormal blood clotting in COVID-19 patients.<\/p>\n<p align=\"justify\">For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yNgDvhU0qUkNjjOKf8XFRrLUeSTj9DXSHeZA8rQ-oCMguo6F7SnO_31Gsnq3175y5LQzEDAmErBHQyXgjb3FQg==\" rel=\"nofollow noopener\" target=\"_blank\">www.Trevena.com<\/a>\u00a0<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company\u2019s strategy, future operations, clinical development and trials of its therapeutic candidates, plans for potential future product candidates, commercialization of approved drug products and other statements containing the words \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cobjective,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201csuggest,\u201d \u201ctarget,\u201d \u201cpotential,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccontinue,\u201d \u201congoing,\u201d or the negative of these terms or similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the commercialization of any approved drug product, the status, timing, costs, results and interpretation of the Company\u2019s clinical trials or any future trials of any of the Company\u2019s investigational drug candidates; the uncertainties inherent in conducting clinical trials; expectations for regulatory interactions, submissions and approvals, including the Company\u2019s assessment of the discussions with the FDA or other regulatory agencies about any and all of its programs; uncertainties related to the commercialization of OLINVYK; available funding; uncertainties related to the Company\u2019s intellectual property; uncertainties related to the ongoing COVID-19 pandemic, other matters that could affect the availability or commercial potential of the Company\u2019s therapeutic candidates; and other factors discussed in the Risk Factors set forth in the Company\u2019s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings the Company makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent the Company\u2019s views only as of the date hereof. The Company anticipates that subsequent events and developments may cause the Company\u2019s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, except as may be required by law.<\/p>\n<p align=\"justify\">\n        <strong>For more information, please contact:<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Investor Contact:<\/strong>\n      <\/p>\n<p align=\"justify\">Dan Ferry<br \/>Managing Director<br \/>LifeSci Advisors, LLC<br \/>daniel@lifesciadvisors.com<br \/>(617) 430-7576<\/p>\n<p>\n        <strong>PR &amp; Media Contact:<\/strong>\n      <\/p>\n<p>Sasha Bennett<br \/>Director<br \/>Clyde Group<br \/>Sasha.Bennett@clydegroup.com<br \/>(239) 248-3409<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNzY5NiM0MTIyNDIyIzIwMDUwMzQ=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/f8cbcfa4-b55f-446f-907f-0742d4848b80\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>&#8212; Models demonstrate substantial overall cost savings for hospitals when using OLINVYK compared to IV morphine in postoperative care &#8212; CHESTERBROOK, Pa., April 15, 2021 (GLOBE NEWSWIRE) &#8212; Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced two poster presentations at the AMCP 2021 Annual Meeting. The conference was held virtually from April 13th to 14th, 2021. The posters highlight two health economic models developed for OLINVYK (oliceridine) injection, which estimate the budget impact of OLINVYK compared to IV morphine when used on-demand in a hospital setting for postoperative pain. A \u201cBase Case\u201d model assumes a broad patient population. A \u201cHigh Risk\u201d model &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/trevena-inc-announces-presentations-of-olinvyk-health-economic-models-at-amcp-2021-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Trevena, Inc. Announces Presentations of OLINVYK\u2122 Health Economic Models at AMCP 2021 Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-476708","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Trevena, Inc. Announces Presentations of OLINVYK\u2122 Health Economic Models at AMCP 2021 Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/trevena-inc-announces-presentations-of-olinvyk-health-economic-models-at-amcp-2021-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Trevena, Inc. Announces Presentations of OLINVYK\u2122 Health Economic Models at AMCP 2021 Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"&#8212; Models demonstrate substantial overall cost savings for hospitals when using OLINVYK compared to IV morphine in postoperative care &#8212; CHESTERBROOK, Pa., April 15, 2021 (GLOBE NEWSWIRE) &#8212; Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced two poster presentations at the AMCP 2021 Annual Meeting. The conference was held virtually from April 13th to 14th, 2021. The posters highlight two health economic models developed for OLINVYK (oliceridine) injection, which estimate the budget impact of OLINVYK compared to IV morphine when used on-demand in a hospital setting for postoperative pain. A \u201cBase Case\u201d model assumes a broad patient population. A \u201cHigh Risk\u201d model &hellip; Continue reading &quot;Trevena, Inc. Announces Presentations of OLINVYK\u2122 Health Economic Models at AMCP 2021 Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/trevena-inc-announces-presentations-of-olinvyk-health-economic-models-at-amcp-2021-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-15T11:33:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNzY5NiM0MTIyNDIyIzIwMDUwMzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevena-inc-announces-presentations-of-olinvyk-health-economic-models-at-amcp-2021-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevena-inc-announces-presentations-of-olinvyk-health-economic-models-at-amcp-2021-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Trevena, Inc. Announces Presentations of OLINVYK\u2122 Health Economic Models at AMCP 2021 Annual Meeting\",\"datePublished\":\"2021-04-15T11:33:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevena-inc-announces-presentations-of-olinvyk-health-economic-models-at-amcp-2021-annual-meeting\\\/\"},\"wordCount\":1096,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevena-inc-announces-presentations-of-olinvyk-health-economic-models-at-amcp-2021-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNzY5NiM0MTIyNDIyIzIwMDUwMzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevena-inc-announces-presentations-of-olinvyk-health-economic-models-at-amcp-2021-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevena-inc-announces-presentations-of-olinvyk-health-economic-models-at-amcp-2021-annual-meeting\\\/\",\"name\":\"Trevena, Inc. Announces Presentations of OLINVYK\u2122 Health Economic Models at AMCP 2021 Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevena-inc-announces-presentations-of-olinvyk-health-economic-models-at-amcp-2021-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevena-inc-announces-presentations-of-olinvyk-health-economic-models-at-amcp-2021-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNzY5NiM0MTIyNDIyIzIwMDUwMzQ=\",\"datePublished\":\"2021-04-15T11:33:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevena-inc-announces-presentations-of-olinvyk-health-economic-models-at-amcp-2021-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevena-inc-announces-presentations-of-olinvyk-health-economic-models-at-amcp-2021-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevena-inc-announces-presentations-of-olinvyk-health-economic-models-at-amcp-2021-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNzY5NiM0MTIyNDIyIzIwMDUwMzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNzY5NiM0MTIyNDIyIzIwMDUwMzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevena-inc-announces-presentations-of-olinvyk-health-economic-models-at-amcp-2021-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Trevena, Inc. Announces Presentations of OLINVYK\u2122 Health Economic Models at AMCP 2021 Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Trevena, Inc. Announces Presentations of OLINVYK\u2122 Health Economic Models at AMCP 2021 Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/trevena-inc-announces-presentations-of-olinvyk-health-economic-models-at-amcp-2021-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Trevena, Inc. Announces Presentations of OLINVYK\u2122 Health Economic Models at AMCP 2021 Annual Meeting - Market Newsdesk","og_description":"&#8212; Models demonstrate substantial overall cost savings for hospitals when using OLINVYK compared to IV morphine in postoperative care &#8212; CHESTERBROOK, Pa., April 15, 2021 (GLOBE NEWSWIRE) &#8212; Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced two poster presentations at the AMCP 2021 Annual Meeting. The conference was held virtually from April 13th to 14th, 2021. The posters highlight two health economic models developed for OLINVYK (oliceridine) injection, which estimate the budget impact of OLINVYK compared to IV morphine when used on-demand in a hospital setting for postoperative pain. A \u201cBase Case\u201d model assumes a broad patient population. A \u201cHigh Risk\u201d model &hellip; Continue reading \"Trevena, Inc. Announces Presentations of OLINVYK\u2122 Health Economic Models at AMCP 2021 Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/trevena-inc-announces-presentations-of-olinvyk-health-economic-models-at-amcp-2021-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-15T11:33:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNzY5NiM0MTIyNDIyIzIwMDUwMzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevena-inc-announces-presentations-of-olinvyk-health-economic-models-at-amcp-2021-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevena-inc-announces-presentations-of-olinvyk-health-economic-models-at-amcp-2021-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Trevena, Inc. Announces Presentations of OLINVYK\u2122 Health Economic Models at AMCP 2021 Annual Meeting","datePublished":"2021-04-15T11:33:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevena-inc-announces-presentations-of-olinvyk-health-economic-models-at-amcp-2021-annual-meeting\/"},"wordCount":1096,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevena-inc-announces-presentations-of-olinvyk-health-economic-models-at-amcp-2021-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNzY5NiM0MTIyNDIyIzIwMDUwMzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevena-inc-announces-presentations-of-olinvyk-health-economic-models-at-amcp-2021-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/trevena-inc-announces-presentations-of-olinvyk-health-economic-models-at-amcp-2021-annual-meeting\/","name":"Trevena, Inc. Announces Presentations of OLINVYK\u2122 Health Economic Models at AMCP 2021 Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevena-inc-announces-presentations-of-olinvyk-health-economic-models-at-amcp-2021-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevena-inc-announces-presentations-of-olinvyk-health-economic-models-at-amcp-2021-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNzY5NiM0MTIyNDIyIzIwMDUwMzQ=","datePublished":"2021-04-15T11:33:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevena-inc-announces-presentations-of-olinvyk-health-economic-models-at-amcp-2021-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/trevena-inc-announces-presentations-of-olinvyk-health-economic-models-at-amcp-2021-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevena-inc-announces-presentations-of-olinvyk-health-economic-models-at-amcp-2021-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNzY5NiM0MTIyNDIyIzIwMDUwMzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNzY5NiM0MTIyNDIyIzIwMDUwMzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevena-inc-announces-presentations-of-olinvyk-health-economic-models-at-amcp-2021-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Trevena, Inc. Announces Presentations of OLINVYK\u2122 Health Economic Models at AMCP 2021 Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/476708","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=476708"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/476708\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=476708"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=476708"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=476708"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}